News
GBIM
0.0001
NaN%
--
Weekly Report: what happened at GBIM last week (0504-0508)?
Weekly Report · 5d ago
Weekly Report: what happened at GBIM last week (0427-0501)?
Weekly Report · 05/04 09:27
Weekly Report: what happened at GBIM last week (0420-0424)?
Weekly Report · 04/27 09:28
Weekly Report: what happened at GBIM last week (0413-0417)?
Weekly Report · 04/20 09:27
Weekly Report: what happened at GBIM last week (0406-0410)?
Weekly Report · 04/13 09:28
Weekly Report: what happened at GBIM last week (0330-0403)?
Weekly Report · 04/06 09:28
Weekly Report: what happened at GBIM last week (0323-0327)?
Weekly Report · 03/30 09:28
Weekly Report: what happened at GBIM last week (0316-0320)?
Weekly Report · 03/23 09:27
Weekly Report: what happened at GBIM last week (0309-0313)?
Weekly Report · 03/16 09:27
Weekly Report: what happened at GBIM last week (0302-0306)?
Weekly Report · 03/09 09:27
Weekly Report: what happened at GBIM last week (0223-0227)?
Weekly Report · 03/02 09:27
Weekly Report: what happened at GBIM last week (0216-0220)?
Weekly Report · 02/23 09:27
Weekly Report: what happened at GBIM last week (0209-0213)?
Weekly Report · 02/16 09:27
Weekly Report: what happened at GBIM last week (0202-0206)?
Weekly Report · 02/09 09:27
Weekly Report: what happened at GBIM last week (0126-0130)?
Weekly Report · 02/02 09:27
Weekly Report: what happened at GBIM last week (0119-0123)?
Weekly Report · 01/26 09:27
Weekly Report: what happened at GBIM last week (0112-0116)?
Weekly Report · 01/19 09:30
Weekly Report: what happened at GBIM last week (0105-0109)?
Weekly Report · 01/12 09:29
Weekly Report: what happened at GBIM last week (1229-0102)?
Weekly Report · 01/05 09:27
Weekly Report: what happened at GBIM last week (1222-1226)?
Weekly Report · 12/29/2025 09:27
More
Webull provides a variety of real-time GBIM stock news. You can receive the latest news about Globeimmune through multiple platforms. This information may help you make smarter investment decisions.
About GBIM
GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.